FrancophonIA/ELRC3.0 huggingface dataset:
English: Pack sizes: 14, 20, 28, 56, 168 or 196 film-coated tablets and multipacks containing 168 (3x56) or 196 (7x28) film-coated tablets.
Croatian: Veličine pakiranja: 14, 20, 28, 56, 168 ili 196 filmom obloženih tableta i višestruka pakiranja koja sadrže 168 (3x56) ili 196 (7x28) filmom obloženih tableta.
English: Entresto 97 mg/103 mg film-coated tablets
Croatian: Entresto 97 mg/103 mg filmom obložene tablete
English: Entresto 24 mg/26 mg film-coated tablets
Croatian: Entresto 24 mg/26 mg filmom obložene tablete
English: Entresto 49 mg/51 mg film-coated tablets are pale yellow oval tablets with “NVR” on one side and “L1” on the other side.
Croatian: Entresto 49 mg/51 mg filmom obložene tablete su blijedo žute ovalne tablete s oznakom „NVR“ s jedne strane i „L1“ s druge strane.
English: Entresto 24 mg/26 mg film-coated tablets Entresto 49 mg/51 mg film-coated tablets Entresto 97 mg/103 mg film-coated tablets
Croatian: Entresto 24 mg/26 mg filmom obložene tablete Entresto 49 mg/51 mg filmom obložene tablete Entresto 97 mg/103 mg filmom obložene tablete
English: Entresto 49 mg/51 mg film-coated tablets
Croatian: Entresto 49 mg/51 mg filmom obložene tablete
English: In PARADIGM-HF, renal impairment was reported in 10.1% of Entresto-treated patients and 11.5% of enalapril-treated patients.
Croatian: U ispitivanju PARADIGM-HF, oštećenje bubrega je prijavljeno u 10,1% bolesnika liječenih Entrestom te u 11,5% bolesnika liječenih enalaprilom.
English: Pack sizes: 14, 20, 28, 56 or 196 film-coated tablets and multipacks containing 196 (7x28) film-coated tablets.
Croatian: Veličine pakiranja: 14, 20, 28, 56 ili 196 filmom obloženih tableta i višestruka pakiranja koja sadrže 196 (7x28) filmom obloženih tableta.
English: ≥49 mg sacubitril/51 mg valsartan/kg/day (≤0.72-fold the maximum recommended human dose [MRHD] on the basis of AUC) and rabbits at doses ≥4.9 mg sacubitril/5.1 mg valsartan/kg/day (2-fold and 0.03-fold the MRHD on the basis of valsartan and LBQ657 AUC, respectively).
Croatian: Liječenje Entrestom tijekom organogeneze rezultiralo je povećanom embriofetalnom smrtnosti u štakora pri dozama ≥49 mg sakubitrila/51 mg valsartana/kg/dan (≤0,72 puta najveće preporučene doze za ljude [MRHD] na temelju AUC-a) i u zečeva pri dozama ≥4,9 mg sakubitrila/5,1 mg valsartana/kg/dan (2 odnosno 0,03 puta MRHD-a na temelju AUC-a valsartana, odnosno LBQ657).
English: Entresto 24 mg/26 mg film-coated tablets Entresto 49 mg/51 mg film-coated tablets Entresto 97 mg/103 mg film-coated tablets sacubitril/valsartan
Croatian: Entresto 24 mg/26 mg filmom obložene tablete Entresto 49 mg/51 mg filmom obložene tablete Entresto 97 mg/103 mg filmom obložene tablete sakubitril/valsartan
English: Entresto should not be co-administered with an ACE inhibitor or an ARB. Due to the potential risk of angioedema when used concomitantly with an ACE inhibitor, it must not be started for at least 36 hours after discontinuing ACE inhibitor therapy (see sections 4.3, 4.4 and 4.5).
Croatian: Zbog potencijalnog rizika od angioedema kada se primjenjuje istodobno s ACE inhibitorom, on se ne smije uvesti u terapiju najmanje 36 sati nakon prekida terapije ACE inhibitorom (vidjeti dijelove 4.3, 4.4 i 4.5).
English: Entresto must not be administered until 36 hours after discontinuing ACE inhibitor therapy.
Croatian: Entresto se ne smije primjenjivati do 36 sati nakon prekida terapije ACE inhibitorom.
English: If you have been taking an ACE inhibitor, wait 36 hours after taking the last dose of the ACE inhibitor before starting to take Entresto (see “Do not take Entresto”).
Croatian: Ako uzimate ACE inhibitor, pričekajte 36 sati nakon uzimanja posljednje doze ACE inhibitora prije nego počnete uzimati Entresto (vidjeti „Uzimanje drugih lijekova“).
English: Therefore, when initiating therapy with Entresto in patients receiving metformin, the clinical status of the patient should be evaluated.
Croatian: Stoga je potrebno ocijeniti klinički status bolesnika kada se započinje terapija Entrestom u bolesnika koji primaju metformin.
English: Entresto contains valsartan, and therefore should not be co-administered with another ARB containing product (see section 4.4).
Croatian: Interakcije koje rezultiraju time da se ne preporučuje istodobna primjena Entresto sadrži valsartan pa se stoga ne smije primjenjivati zajedno s drugim lijekom koji sadrži ARB (vidjeti dio 4.4).
English: In a 7-day valsartan-controlled study in patients with reduced ejection fraction (HFrEF), administration of Entresto resulted in an initial increase in natriuresis, increased urine cGMP, and decreased plasma levels of mid-regional pro-atrial natriuretic peptide (MR-proANP) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) compared to valsartan.
Croatian: povećanjem koncentracije cGMP-a u mokraći te smanjenim razinama u plazmi srednje-regionalnog proatrijalnog natriuretskog peptida (MR-proANP) i N-terminalnog prohormona moždanog natriuretskog peptida (NT-proBNP) u usporedbi s valsartanom.
English: Therefore, co-administration of Entresto with inhibitors of OATP1B1, OATP1B3, OAT3 (e.g. rifampicin, ciclosporin), OAT1 (e.g. tenofovir,
Croatian: Stoga istodobna primjena Entresta s inhibitorima OATP1B1, OATP1B3, OAT3 (npr. rifampicinom, ciklosporinom), OAT1 (npr. tenofovirom, cidofovirom) ili MRP2 (npr. ritonavirom) može povećati sistemsku izloženost LBQ657 ili valsartanu.
English: What Entresto looks like and contents of the pack Entresto 24 mg/26 mg film-coated tablets are violet-white oval tablets with “NVR” on one side and “LZ” on the other side.
Croatian: Entresto 24 mg/26 mg filmom obložene tablete su ljubičasto bijele ovalne tablete s oznakom „NVR“ s jedne strane i „LZ“ s druge strane.
English: Entresto must not be started until 36 hours after taking the last dose of ACE inhibitor therapy.
Croatian: Entresto se ne smije započinjati do 36 sati nakon uzimanja zadnje doze terapije ACE inhibitorom.
English: Entresto 49 mg/51 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Croatian: Entresto 49 mg/51 mg filmom obložene tablete Hipromeloza, supstitucijski tip 2910 (3 mPa s) Titanijev dioksid (E171) Makrogol 4000
English: The combination of Entresto with aliskiren-containing products is contraindicated in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 ml/min/1.73 m2) (see sections 4.3 and 4.5).
Croatian: Kombinacija Entresta s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolesti ili u bolesnika s oštećenjem bubrega (eGFR <60 ml/min/1,73 m (vidjeti dijelove 4.3 i 4.5).
English: Entresto 97 mg/103 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Croatian: Entresto 97 mg/103 mg filmom obložene tablete Hipromeloza, supstitucijski tip 2910 (3 mPa s) Titanijev dioksid (E171) Makrogol 4000
English: The concomitant use of Entresto with aliskiren-containing products is contraindicated in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 ml/min/1.73 m2) (see section 4.3).
Croatian: Istodobna primjena Entresta i lijekova koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolesti ili u bolesnika s oštećenjem bubrega (eGFR <60 ml/min/1,73 m2) (vidjeti dio 4.3).
English: Entresto 24 mg/26 mg film-coated tablets Hypromellose, substitution type 2910 (3 mPa·s) Titanium dioxide (E171) Macrogol 4000
Croatian: Entresto 24 mg/26 mg filmom obložene tablete Hipromeloza, supstitucijski tip 2910 (3 mPa s) Titanijev dioksid (E171) Makrogol 4000
English: Entresto 97 mg/103 mg tablets sacubitril/valsartan
Croatian: Entresto 97 mg/103 mg tablete sakubitril/valsartan
English: Entresto 24 mg/26 mg tablets sacubitril/valsartan
Croatian: Entresto 24 mg/26 mg tablete sakubitril/valsartan
English: Approximate tablet dimensions 13.1 mm x 5.2 mm Entresto 97 mg/103 mg film-coated tablets are light pink oval tablets with “NVR” on one side and “L11” on the other side.
Croatian: Entresto 97 mg/103 mg filmom obložene tablete su svijetlo ružičaste ovalne tablete s oznakom „NVR“ s jedne strane i „L11“ s druge strane.
English: Entresto 24 mg/26 mg film-coated tablets sacubitril/valsartan
Croatian: Entresto 24 mg/26 mg filmom obložene tablete sakubitril/valsartan
English: Entresto 97 mg/103 mg film-coated tablets sacubitril/valsartan
Croatian: Entresto 97 mg/103 mg filmom obložene tablete sakubitril/valsartan
English: Entresto 49 mg/51 mg tablets sacubitril/valsartan
Croatian: Entresto 49 mg/51 mg tablete sakubitril/valsartan
English: If you stop taking Entresto, wait 36 hours after taking your last dose of Entresto before starting an ACE inhibitor.
Croatian: Ako prestanete uzimate Entresto, pričekajte 36 sati nakon uzimanja posljednje doze Entresta prije nego počnete uzimati ACE inhibitor (vidjeti „Uzimanje drugih lijekova“).
English: Entresto 49 mg/51 mg film-coated tablets sacubitril/valsartan
Croatian: Entresto 49 mg/51 mg filmom obložene tablete sakubitril/valsartan
English: A slight increase in two foetal skeletal variations (misshapen sternebra, sternebra bipartite ossification) was observed in rabbits at an Entresto dose of
Croatian: Blago povećanje dviju varijacija fetusnog skeleta (deformirana sternebra, dvostrana osifikacija sternebre) bilo je uočeno u zečeva pri dozi Entresta od 4,9 mg sakubitrila/5,1 mg valsartana/kg/dan.
English: SN:
Croatian: D.
English: The infusion lasts 2 hours.
Croatian: Infuzija mora trajati 2 sata.
English: This reduces bone loss.
Croatian: Time se smanjuje gubitak kostiju.
English: Patients should also take vitamin D and calcium supplements.
Croatian: Bolesnici također moraju uzimati vitamin D i dodatke kalcija.
English: It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use.
Croatian: Objašnjava kako je Agencija procijenila lijek da bi preporučila njegovo odobrenje u EU-u te uvjete za njegovu primjenu.
English: The full EPAR for Ibandronic acid Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Ibandronatna kiselina Accord nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The full EPAR for the reference medicines can also be found on the Agency's website.
Croatian: Cjeloviti EPAR za referentne lijekove nalazi se i na internetskim stranicama Agencije.
English: This will normally bring the blood calcium level down to normal levels within a week.
Croatian: To u pravilu razine kalcija u krvi vraća u normalu unutar tjedan dana.
English: This means that Ibandronic acid Accord contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU).
Croatian: To znači da Ibandronatna kiselina Accord sadržava istu djelatnu tvar i djeluje na isti način kao i „referentni lijek” koji je već odobren u Europskoj uniji (EU).
English: For the prevention of skeletal events or the treatment of hypercalcaemia in cancer patients, treatment with this medicine should only be started by a doctor who has experience in the treatment of cancer.
Croatian: Za sprječavanje koštanih problema ili liječenje hiperkalcemije u oboljelih od raka, terapiju ovim lijekom može započeti samo liječnik s iskustvom u liječenju raka.
English: • prevent ‘skeletal events' (fractures or bone complications requiring treatment) in patients with breast cancer and bone metastases (when the cancer has spread to the bone);
Croatian: • sprječavanje „koštanih problema” (fraktura ili komplikacija s kostima koje zahtijevaju liječenje u bolesnika s rakom dojke i metastazama u kostima (kad se rak proširio na kosti);
English: • treat hypercalcaemia (high levels of calcium in the blood) caused by tumours.
Croatian: • liječenje hiperkalcemije (visoke razine kalcija u krvi) koju uzrokuju tumori.
English: Its effect in reducing the risk of spine fractures has been shown in studies, but its effect on the risk of fractures of the neck of the femur (the top of the thighbone) has not been established.
Croatian: Njegov učinak na smanjenje rizika od fraktura kralježnice utvrđen je u ispitivanjima, no učinak dotičnog lijeka na rizik od fraktura vrha femura (bedrene kosti) nije utvrđen.
English: Patients with tumours can have high levels of calcium in their blood, released from the bones.
Croatian: Bolesnici s tumorima mogu imati visoke količine kalcija u krvi koji se izlučuje iz kostiju.
English: Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicines, Bondronat and Bonviva, and do not need to be repeated for Ibandronic acid Accord.
Croatian: Ispitivanja o koristima i rizicima djelatne tvari pri odobrenoj primjeni već su provedena za referentne lijekove, Bondronat i Bonviva, te ih ne treba ponavljati za lijek Ibandronatna kiselina Accord.
English: As for every medicine, the company provided studies on the quality of Ibandronic acid Accord.
Croatian: Kao i za svaki lijek, tvrtka je dostavila ispitivanja o kvaliteti lijeka Ibandronatna kiselina Accord.
English: Because Ibandronic acid Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicines'.
Croatian: Budući da je Ibandronatna kiselina Accord generički lijek, smatra se da su njegove koristi i rizici isti kao i oni referentnih lijekova.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Ibandronic acid Accord has been shown to be comparable to Bondronat and Bonviva.
Croatian: Europska agencija za lijekove zaključila je kako je, u skladu sa zahtjevima EU-a, potvrđeno da je lijek Ibandronatna kiselina Accord usporediv s lijekovima Bondronat i Bonviva.
English: Osteonecrosis of the jaw is a condition affecting the bones of the jaw, which could lead to pain, sores in the mouth or loose teeth.
Croatian: Osteonekroza čeljusti poremećaj je koji utječe na čeljusne kosti, što može uzrokovati bolove, rane u ustima ili klimanje zubi.
English: It stops the action of osteoclasts, the cells in the body that are involved in breaking down the bone tissue.
Croatian: Zaustavlja aktivnost osteoklasta, stanica u tijelu koje su uključene u razgradnju koštanog tkiva.
English: There was no need for ‘bioequivalence' studies to investigate whether Ibandronic acid Accord is absorbed similarly to the reference medicines to produce the same level of the active substance in the blood.
Croatian: Nije bilo potrebe za ispitivanjima bioekvivalencije kako bi se istražilo apsorbira li se Ibandronatna kiselina Accord na sličan način kao i referentni lijekovi radi proizvodnje jednake razine djelatne tvari u krvi.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ibandronic acid Accord have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Ibandronatna kiselina Accord također se nalaze u sažetku opisa svojstava i u uputi o lijeku.
English: For the treatment of osteoporosis, Ibandronic acid Accord is given as an injection into a vein once every three months.
Croatian: Za liječenje osteoporoze, Ibandronatna kiselina Accord daje se kao injekcija u venu jednom svaka tri mjeseca.
English: By preventing the breakdown of bones, Ibandronic acid Accord also helps to reduce the amount of calcium released into the blood.
Croatian: Sprječavanjem razgradnje kostiju, ibandronatna kiselina također doprinosi smanjenju količine kalcija koji se izlučuje u krv.
English: Ibandronic acid Accord is available as a solution for injection (3 mg) in a pre-filled syringe and as a concentrate (2 mg and 6 mg) to be made up into a solution for infusion (drip) into a vein.
Croatian: Lijek Ibandronatna kiselina Accord dostupan je u obliku otopine za injekciju (3 mg) u napunjenoj brizgalici i kao koncentrat (2 mg i 6 mg) za pripremu otopine za infuziju (drip) u venu.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ibandronic acid Accord on 19 November 2012.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet lijeka Ibandronatna kiselina Accord koje vrijedi na prostoru Europske unije od 19. studenoga 2012.
English: Ibandronic acid Accord concentrate for solution for infusion (drip) is used in adults to:
Croatian: Koncentrat za otopinu za infuziju (drip) Ibandronatna kiselina Accord koristi se u odraslih za:
English: The company that markets Ibandronic acid Accord will provide a card to inform patients receiving Ibandronic acid Accord infusion about the risk of osteonecrosis of the jaw and to instruct them to contact their doctor if they get symptoms.
Croatian: Tvrtka koja lijek Ibandronatna kiselina Accord stavlja u promet osigurat će karticu s informacijama za bolesnike koji primaju infuziju lijeka Ibandronatna kiselina Accord o rizicima osteonekroze čeljusti te s uputama da kontaktiraju svojeg liječnika u slučaju pojave simptoma.
English: This is a summary of the European public assessment report (EPAR) for Ibandronic acid Accord.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Ibandronatna kiselina Accord.
English: Ibandronic acid Accord solution for injection is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and are at risk of developing bone fractures (breaks).
Croatian: Otopina za injekciju Ibandronatna kiselina Accord koristi se za liječenje osteoporoze (bolesti koja kosti čini krhkima) u žena koje su prošle menopauzu i izložene su riziku razvoja fraktura (lomova) kostiju.
English: In the treatment of hypercalcaemia caused by tumours, Ibandronic acid Accord is given into a vein as an infusion of 2 or 4 mg, depending on how severe the hypercalcaemia is.
Croatian: U liječenju hiperkalcemije uzrokovane tumorima, Ibandronatna kiselina Accord daje se u venu kao infuzija od 2 mg ili 4 mg, ovisno o težini hiperkalcemije.
English: This is because Ibandronic acid Accord is given by infusion or injection into a vein, so the active substance is delivered straight into the bloodstream.
Croatian: Razlog tome je činjenica da se Ibandronatna kiselina Accord daje infuzijom ili injekcijom u venu te djelatna tvar odmah ulazi u krvotok.
English: In the prevention of skeletal events in patients with breast cancer and bone metastases, Ibandronic acid Accord is given into a vein as a 6 mg infusion lasting at least 15 minutes every three to four weeks.
Croatian: Za sprječavanje koštanih problema u bolesnika s rakom dojke i metastazama u kostima, Ibandronatna kiselina Accord daje se u venu kao infuzija od 6 mg u trajanju od barem 15 minuta svaka tri do četiri tjedna.
English: What measures are being taken to ensure the safe and effective use of Ibandronic acid Accord?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Ibandronatna kiselina Accord?
English: For more information about treatment with Ibandronic acid Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Ibandronatna kiselina Accord pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svojem liječniku ili ljekarniku.
English: Other information about Ibandronic acid Accord
Croatian: Ostale informacije o lijeku Ibandronatna kiselina Accord
English: It is not intended to provide practical advice on how to use Ibandronic acid Accord.
Croatian: Svrha sažetka nije davati praktične savjete o korištenju lijeka Ibandronatna kiselina Accord.
English: Ibandronic acid Accord is a medicine used to treat certain conditions affecting bones and blood calcium.
Croatian: Ibandronatna kiselina Accord lijek je kojim se liječe određena stanja koja utječu na kalcij u kostima i krvi.
English: The Agency recommended that Ibandronic acid Accord be approved for use in the EU.
Croatian: Agencija je preporučila izdavanje odobrenja za stavljanje u promet lijeka Ibandronatna kiselina Accord u EU-u.
English: What is Ibandronic acid Accord and what is it used for?
Croatian: Što je Ibandronatna kiselina Accord i za što se koristi?
English: What are the benefits and risks of Ibandronic acid Accord?
Croatian: Koje su koristi i rizici od lijeka Ibandronatna kiselina Accord?
English: The reduction of bone loss helps to make bones less likely to break in cancer patients with bone metastases and in women with osteoporosis.
Croatian: Smanjenje gubitka kostiju umanjuje i mogućnost lomova kostiju u oboljelih od raka s metastazama u kostima te u žena s osteoporozom.
English: Ibandronic acid Accord contains the active substance ibandronic acid and is a ‘generic medicine'.
Croatian: Ibandronatna kiselina Accord sadržava djelatnu tvar ibandronatnu kiselinu te je „generički lijek”.
English: Patients with moderate or severe kidney problems should receive Ibandronic acid Accord infusions at a lower dose over an hour.
Croatian: Bolesnici s umjerenim do teškim bubrežnim problemima trebaju primiti infuzije lijeka u manjim dozama u trajanju od preko sat vremena.
English: For practical information about using Ibandronic acid Accord, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Ibandronatna kiselina Accord bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svojem liječniku ili ljekarniku.
English: The active substance in Ibandronic acid Accord, ibandronic acid, is a bisphosphonate.
Croatian: Djelatna tvar lijeka Ibandronatna kiselina Accord, ibandronatna kiselina, je biofosfonat.
English: The reference medicines for Ibandronic acid Accord are Bondronat and Bonviva.
Croatian: Referentni lijekovi za lijek Ibandronatna kiselina Accord su Bondronat i Bonviva.
English: Therefore, the Agency's view was that, as for Bondronat and Bonviva, the benefit outweighs the identified risk.
Croatian: Stoga je stav Agencije da korist nadmašuje identificirani rizik, kao i za lijekove Bondronat i Bonviva.
English: Ibandronic acid Accord ibandronic acid
Croatian: Ibandronatna kiselina Accord ibandronatna kiselina
English: Why is Ibandronic acid Accord approved?
Croatian: Zašto je lijek Ibandronatna kiselina Accord odobren?
English: How is Ibandronic acid Accord used?
Croatian: Kako se Ibandronatna kiselina Accord koristi?
English: How does Ibandronic acid Accord work?
Croatian: Kako djeluje Ibandronatna kiselina Accord?
English: How has Ibandronic acid Accord been studied?
Croatian: Kako je Ibandronatna kiselina Accord ispitivan?
English: Concentrate: 1.5ml Solvent: 4.5 ml
Croatian: koncentrat: 1,5 ml; otapalo: 4,5 ml
English: EU/1/11/676/001Jevtana 60 mg Concentrate and solvent for solution for infusion
Croatian: EU/1/11/676/001 Jevtana
English: Strength Pharmaceutical Form Route of Administration
Croatian: Doza Farmaceutski oblik Način primjene Unutarnje pakovanje
English: Intravenous use Concentrate: vial (glass) Solvent: vial (glass)
Croatian: Za primjenu u venu koncentrat: bočica (staklo); otapalo: bočica (staklo)
English: (Invented) name
Croatian: EU broj odobrenja (Zaštićeni) naziv lijeka
English: Date of first authorisation: 26 July 2017
Croatian: Datum prvog odobrenja: 26 srpanj 2017
English: What Vosevi is and what it is used for
Croatian: Što je Vosevi i za što se koristi
English: • Your doctor can decide if you should take Vosevi and for how long;
Croatian: • Vaš liječnik može odlučiti trebate li uzimati lijek Vosevi i koliko dugo;
English: STIMULANTS Modafinil
Croatian: STIMULANSI Modafinil
English: d. These are medicinal products within class where similar interactions could be predicted.
Croatian: d. Ovo su lijekovi iz skupine u kojoj se mogu predvidjeti slične interakcije.
English: f. Data obtained from transiently transfected replicons.
Croatian: f. Podaci dobiveni iz prolazno transficiranih replikona.
English: The human relevance of this finding is not known.
Croatian: Značajnost tog otkrića za ljude nije poznata.
English: If you take more Vosevi than you should
Croatian: Ako uzmete više lijeka Vosevi nego što ste trebali